97-18623. Notice Pursuant to the National Cooperative Research and Production Act of 1993134a Consortium

[Federal Register Volume 62, Number 136 (Wednesday, July 16, 1997)]
[Notices]
[Page 38120]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-18623]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--134a Consortium

    Notice is hereby given that, on June 12, 1997, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. Sec. 4301 et seq. (``the Act''), the 134a Consortium has 
filed written notifications simultaneously with the Attorney General 
and the Federal Trade Commission disclosing (1) the identities of the 
parties and (2) the nature and objective of the venture. The 
notifications were filed for the purpose of invoking the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances. Pursuant to Section 6(b) of the 
Act, the identities of the parties to the joint venture which shall be 
known as the 134a Consortium are: Boehringer Ingelheim Pharmaceuticals, 
Inc., Ridgefield, Ct; Institut de Recherches Internationales Servier, 
Paris, France; IVAX, Miami, Fl; Medeva Americas, Inc., Rochester, Ny; 
Rhone-Poulenc Rorer Pharmaceuticals, Inc., Collegeville, Pa; and 3M 
Pharmaceuticals, a division of Minnesota Mining and Manufacturing 
Company, St. Paul, Mn. The general planned activities are to explore 
and possibly implement options for acceptance testing of HFA-134a for 
use as a propellant in pharmaceutical aerosols.
Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 97-18623 Filed 7-15-97; 8:45 am]
BILLING CODE 4410-11-M